A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 8, 2012, Pages 1948-1960

  Zelmer, Andrea ^a   Carroll, Paul ^b   Andreu, Nuria ^c   Hagens, Kristine ^d   Mahlo, Jacqueline ^d   Redinger, Natalja ^d   Robertson, Brian D ^c   Wiles, Siouxsie ^c,e   Ward, Theresa H ^a   Parish, Tanya ^b,f   Ripoll, Jorge ^g   Bancroft, Gregory J ^a   Schaible, Ulrich E ^a,d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d RESEARCH CENTER BORSTEL   (Germany)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^g INSTITUTE OF COMPUTER SCIENCE   (Greece)

Author keywords

Antibiotics; Drug testing; Mycobacteria; Optical imaging; TB

Indexed keywords

MOXIFLOXACIN; RED FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EX VIVO STUDY; FLUORESCENCE IMAGING; IN VIVO STUDY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STABILITY; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; FLUORESCENCE; GENES, REPORTER; IMAGE PROCESSING, COMPUTER-ASSISTED; LUMINESCENT PROTEINS; LUNG; MICE; MICE, SCID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; WHOLE BODY IMAGING;

EID: 84864528825     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks161     Document Type: Article

References (39)

1. WHO. Tuberculosis. http://www.who.int/mediacentre/factsheets/fs104/en/index.html (23 September 2011, date last accessed).
2. Rowland R, McShane H. Tuberculosis vaccines in clinical trials. Expert Rev Vaccines 2011; 10: 645-58.
3. Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271: 698-702.
4. WHO. Map: Available Data on Anti-TB Drug Resistance, 2010. http://www.who.int/tb/challenges/mdr/drs_maps_feb2011.pdf (23 September 2011, date last accessed).
5. Dorhoi A, Reece ST, Kaufmann SH. For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection. Immunol Rev 2011; 240: 235-51.
6. Russell DG, Cardona PJ, Kim MJ et al. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 2009; 10: 943-8.
7. Tsai MC, Chakravarty S, Zhu G et al. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol 2006; 8: 218-32.
8. Orme IM. The mouse as a useful model of tuberculosis. Tuberculosis (Edinb) 2003; 83: 112-5.
9. Harper J, Skerry C, Davis SL et al. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 2012; 205: 595-602.
10. Apt A, Kramnik I. Man and mouse TB: contradictions and solutions. Tuberculosis (Edinb) 2009; 89: 195-8.
11. Ehlers S. Lazy, dynamic or minimally recrudescent? On the elusive nature and location of the Mycobacterium responsible for latent tuberculosis. Infection 2009; 37: 87-95.
12. Patel K, Jhamb SS, Singh PP. Models of latent tuberculosis: their salient features, limitations, and development. J Lab Physicians 2011; 3: 75-9.
13. Contag CH, Contag PR, Mullins JI et al. Photonic detection of bacterial pathogens in living hosts. Mol Microbiol 1995; 18: 593-603.
14. Wiles S, Robertson BD, Frankel G et al. Bioluminescent monitoring of in vivo colonization and clearance dynamics by light-emitting bacteria. Methods Mol Biol 2009; 574: 137-53.
15. Hardy J, Margolis JJ, Contag CH. Induced biliary excretion of Listeria monocytogenes. Infect Immun 2006; 74: 1819-27.
16. Zhao M, Yang M, Baranov E et al. Spatial-temporal imaging of bacterial infection and antibiotic response in intact animals. Proc Natl Acad Sci USA 2001; 98: 9814-8.
17. Zhao M, Yang M, Li XM et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 2005; 102: 755-60.
18. Andreu N, Zelmer A, Wiles S. Noninvasive biophotonic imaging for studies of infectious disease. FEMS Microbiol Rev 2011; 35: 360-94.
19. Gordon S, Chung G, Andrew P. The application of bacterial luciferase as a reporter gene in mycobacteria. Methods Mol Biol 1998; 101: 235-43.
20. Carroll P, Schreuder LJ, Muwanguzi-Karugaba J et al. Sensitive detection of gene expression in mycobacteria under replicating and non-replicating conditions using optimized far-red reporters. PLoS One 2010; 5: e9823.
21. Deliolanis NC, Kasmieh R, Wurdinger T et al. Performance of the red-shifted fluorescent proteins in deep-tissue molecular imaging applications. J Biomed Opt 2008; 13: 044008.
22. O'Gaora P. Expression of genes in mycobacteria. In: Parish T, Stoker N, eds. Mycobacteria Protocols. Totowa: Humana Press, 1998; 261-73.
23. Guo XV, Monteleone M, Klotzsche M et al. Silencing Mycobacterium smegmatis by using tetracycline repressors. J Bacteriol 2007; 189: 4614-23.
24. O'Gaora P. Expression of genes in mycobacteria. In: Parish T, Stoker N, eds. Mycobacteria Protocols. Totowa: Humana Press, 1998; 129-44.
25. Rice BW, Cable MD, Nelson MB. In vivo imaging of light-emitting probes. J Biomed Opt 2001; 6: 432-40.
26. Shaner NC, Campbell RE, Steinbach PA et al. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 2004; 22: 1567-72.
27. Shcherbo D, Murphy CS, Ermakova GV et al. Far-red fluorescent tags for protein imaging in living tissues. Biochem J 2009; 418: 567-74.
28. Kong Y, Subbian S, Cirillo SL et al. Application of optical imaging to study of extrapulmonary spread by tuberculosis. Tuberculosis (Edinb) 2009; 89 Suppl 1: S15-7.
29. Kong Y, Yao H, Ren H et al. Imaging tuberculosis with endogenous b-lactamase reporter enzyme fluorescence in live mice. Proc Natl Acad Sci USA 2010; 107: 12239-44.
30. Subach FV, Piatkevich KD, Verkhusha VV. Directed molecular evolution to design advanced red fluorescent proteins. Nat Methods 2011; 8: 1019-26.
31. Shcherbo D, Shemiakina II, Ryabova AV et al. Near-infrared fluorescent proteins. Nat Methods 2010; 7: 827-9.
32. Rullas J, Garcia JI, Beltran M et al. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob Agents Chemother 2010; 54: 2262-4.
33. Helaine S, Thompson JA, Watson KG et al. Dynamics of intracellular bacterial replication at the single cell level. Proc Natl Acad Sci USA 2010; 107: 3746-51.
34. Nuermberger E, Tyagi S, Tasneen R et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008; 52: 1522-4.
35. Tasneen R, Li SY, Peloquin CA et al. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011; 55: 5485-92.
36. Lounis N, Gevers T, Van Den Berg J et al. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother 2008; 52: 3568-72.
37. Rosenthal IM, Zhang M, Almeida D et al. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 2008; 178: 989-93.
38. Lenaerts AJ, Gruppo V, Brooks JV et al. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother 2003; 47: 783-5.
39. Jhamb SS, Singh PP. A short-term model for preliminary screening of potential anti-tubercular compounds. Scand J Infect Dis 2009; 41: 886-9.